Education:

Post Graduate Training:

Professional Experience (Academic/Clinical Positions):

Hospital Appointments:

Directorships:

Academic Responsibilities:

Chairman of McKay Department of Urology of Carolinas Medical Center: 

1)      Administration of the University of North Carolina Chapel Hill Urology PGY-4 Resident Rotation at CMC. 

2)      Administration and direct clinical instruction of General

3)      Regular lectures to the Internal Medicine, Family Practice,

4)      Administration of an active clinical research practice that involves 3 full-time clinical research nurses and a basic science prostate cancer lab run by Laura Glasscock, PhD.

Professional Society Memberships:

Patents:

• Roberts Protocol #301 – Phase III, Open-Label, Randomized, Parallel, Active-Control Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients with Advanced Prostate Cancer (Shire Pharmaceuticals).

• LIA-INT-26 – An international phase II randomized, double-blind, multicenter study to determine the tolerability and efficacy of three different doses of liarozole in patients with rising prostate specific antigen levels after definitive treatment (Janssen Pharmaceuticals).

• Abbott M00-244 – A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 mg. Atrasentan in Men with Non-Metastatic, Hormone-Refractory Prostate Cancer (Abbott Pharmaceuticals).

• Abbott M00-258 – A Phase III Extension Study to Evaluate the Safety of 10 mg. Atrasentan in Men with Hormone-Refractory Prostate Cancer (Abbott Pharmaceuticals).

• Abbott M01-366 – A Phase II Study Evaluating the Safety and Efficacy of Atrasentan (ABT-627) in Men with Hormone Naive Prostate Cancer that are Exhibiting Early Signs of Biochemical Failure (Abbott Pharmaceuticals).

• Protocol No. 301 – A Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients with Advanced Prostate Cancer (Hydro Med Sciences).

• Trial DC3-HRPC – A Randomized, Double-Blind, Placebo-Placebo-Controlled Phase III Clinical Trial Evaluating DCVax ä Prostate Autologous Dendritic Cells Loaded with Recombinant Prostate Specific Membrane Antigen (rPSMA) for the Treatment of Metastatic Hormone Refractory Prostate Cancer (Northwest Biotherapeutics Inc.).

• GTX-006-211 – A Phase IIb Study to Determine the Long Term Prostate Cancer Chemoprevention Efficacy and Safety of GTx-006 in Men with High Grade Prostate Intraepithelial Neoplasia (PIN) (Health Decision, Inc.).

• Study No. C-100-12 -- A Multi-Center, Randomized Phase III Study of Adjuvant Oncophageâ Versus Observation in Patients with High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma (Antigenics, Inc.).

• Guilford Pharmaceuticals: Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 12-MonthTrial to Evaluate the Effects of GPI 1485 on Erectile Function in Patients Undergoing BNSRRP for Prostatic Carcinoma.

• REDUCE ARI4006: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer  (GlaxoSmithKline).

• Dendreon P-11: Autologous PAP-Loaded Dendritic Cell Vaccine (APC8015, Provenge™) In Patients With Non-Metastatic Prostate Cancer Who Experience PSA Elevation Following Radical Prostatectomy: A Randomized, Controlled, Double-Blind Trail   (Dendreon Corporation).

• D9902B: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (Provenge®, APC8015) in Asymptomatic Subjects with Gleason Sum ≤ 7, Metastatic, Androgen Independent Prostatic Adenocarcinomas (Dendreon Corporation).

• PB01: An Open Label, Single Arm Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (APC8015F) For Subjects with Objective Disease Progression and Disease-Related Pain on Protocol D9902   (Dendreon Corporation).

Publications: 

2. “Functional characteristics of the Camey ileal bladder”.   Claus G. Roehrborn, Chris M. Teigland, Arthur I. Saglowsky.  Journal of Urology 138:739, 1987.

3. “Harnbleitung mittels ileumschlinge nach Camey - Ergebnisse urogynamischer dutdien”.   Chris M. Teigland and Claus G. Roehrborn.  Aktuelle Urologie 18:11-17, 1987.

4. “Progression of leukoplakia of the bladder to squamous cell carcinoma 19 years After complete urinary diversion”.   Claus G. Roehrborn, Chris M. Teigland, Harry M. Spence.  Journal of Urology 140:603, 1988.

5. “Simultaneous detection of circulating prostate-specific antigen (PSA) - expressing and prostate-specific membrane antigen (PSM) - expressing cells by a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) assay”.   Douglas K. Price, Ph.D., Warden L. Woodard, M.D.,  Chris M. Teigland, M.D.  Urologic Oncology 1:226-233, 1995.

12. “Hand-Assisted Laparoscopic Radical Nephrectomy for Renal Cell Carcinoma with Renal Vein Tumor Thrombus.”  Kent W. Kercher MD, Tien H. Nguyen DO, B. Todd Heniford MD, Pierce B. Irby MD, Chris M. Teigland MD, Department of General Surgery and McKay Department of Urology, Carolinas Medical Center, Charlotte, North Carolina.  In review, Surg Lap Endosc Perc Tech 2003.

13. “Clinical Use of Fluorodeoxyglucose F-18 Positron Emission Tomography for Detection of Renal Cell Carcinoma.”   David E. Kang, Richard L. White Jr., James H. Zuger, Howell C. Sasser, Chris M. Teigland.  Journal of Urology 171 (5): 1806-1809, May 2004.

1. “Potential Hazards of Power Lithotripsy”, Resident Essay Contest, South Central AUA Section Meeting, Houston,  Texas, 1984

2. “Selective Surgery for Testis Tumors”, Paul C. Peters, Chris M. Teigland, AUA Meeting, Atlanta, Georgia, 1985

3. “The Effect of Power Lithotripsy on Renal Parenchyma”, Chris M. Teigland, Ralph V. Clayman, John H. Childers, Third World Congress on Endourology, New York City, New York, 1985

4. “Ultrasonic Lithoptripsy, The Risk of Hearing Loss:, Chris M. Teigland, Ralph V. Clayman, Ross J. Roeser, Third  World Congress on Endourology, New York City, New York, 1985.

5. “Comparative Urodynamic Assessment of Four Different Continent Urinary Diversion:   (Camey, Kock, Ileocecal reservoir, MAINZ pouch)”, Chris M. Teigland, Claus G. Roehrborn, Arthur Sagalowsky, AUA Meeting,  New York City, New York, 1986.

6. “A New Molecular Method to Evaluate Prostate Cancer: detection of circulating prostate cancer cells by a multiplex reverse transcriptase polymerase chain reaction assay”, D.K. Price, W. Woodard, H. Godwin,  C.M. Teigland, 45th Annual Meeting of the American Society of Human Genetics, Minneapolis, MN, October 1995

7. #6 above also presented at the Society for Basic Urologic Research, Chapel Hill, NC,   December 1995.

8. “Prostate Cancer 1996”, CMC Spring Symposium, geriatrics section, Chris M. Teigland, Charlotte, NC, May 25, 1996

9. “Hematogenous dissemination of prostate cancer cells as the result of needle biopsy: detection of circulating prostate cells by a quantitative nested multiplex reverse-transcription PCR assay”, D.K. Price, J. Daniels, D.R. Clontz, C. M. Teigland.  46th Annual Meeting of the American Society of Human Genetics, San Francisco, CA, 1995

10. “Thrombomodulin in vivo and in vitro expression and activity in prostate cancer”, LN Glasscock, JS Hubbard, E Lipford, CM Teigland, DK Price, 90^th American Association of Cancer Research,  Philadelphia, PA,  April 1999, 40: Abstract #3023.

11. “Thrombomodulin regulation of prostate cancer invasion, cell adhesion, and angiogenesis”, LN Glasscock, C. Teigland, ME Perraut, JS Hubbard, DK Price, 91^st Annual Meeting of the AACR, San Francisco, CA, April 2000,  41: Abstract# 1932.

12. “What is the best screening strategy for prostate cancer?”   Family Practice Conference, Renaissance Hotel, Charlotte, NC, May 17, 2000.

13. Poster:   D. Dreau, C. Walsh, W.D. Holder, R.L. White, C.M. Teigland.  Use of Dendritic Cells to Develop a Vaccine  for Prostate Cancer Patients with Advanced Disease.  Society for Basic Urologic Research, Sanibel Harbor, FL, Sept. 9-12, 2000.

14. Kercher KW, Smith TI, Irby PB, Eskind LB, Matthews BD, Heniford BT, Teigland CM.  Impact of the introduction of laparoscopic nephrectomy within a community-based teaching hospital. Society of American Gastrointestinal Endoscopic Surgeons. 8^th World Congress of Endoscopic Surgery, New York, NY, March 13-16, 2002.

15. Trina I. Smith, Brent D. Matthews, Chris M. Teigland, B. Todd Heniford, Kent W. Kercher.  Hand-Assisted Surgery Decreases Operative Time for Laparoscopic Nephrectomy.  Southeastern Surgical Congress, Savannah, Georgia, February 7-11, 2003.

16. Kent W. Kercher, Daniel H. Hayes, Brent D. Matthews, B. Todd Heniford, Amy E. Lincourt, Pierce B. Irby, Chris M. Teigland. Laparoscopic Versus Open Nephrectomy: Outcomes And Cost Analysis In 210 Consecutive Patients. Society of American Gastrointestinal Endoscopic Surgeons, Los Angeles, California, March 10-15, 2003.    (abstract)

17. Kercher KW, Carbonell AM, Harold KL, Irby PB, Matthews BD, Heniford BT, Teigland CM.  Laparoscopic radical nephrectomy for renal cell carcinoma with renal vein tumor thrombus.  To be presented, American College of Surgeons Annual Congress, Chicago, Illinois, Oct 19-23, 2003.   (Video presentation)